Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by ronrydellon Mar 12, 2013 12:15pm

200 Views

Post# 21116467

RE: RE: RE: AGM Summary from trt on I.V.

Then explain the new loan..up from 25MM which in itself was a cushion from 13MM when DM indicated that he expected to pay off the 25MM with licensing agreements that are in itself months overdue.

Bottom line..sounds like licensing either didn't happen or were deferred until AFTER we find out I'd Assure works or not. (If I was the licensor, I'd also want to see BEFORE I'd pay)

Bullboard Posts

How one company is disrupting PoC testing